RedHill Biopharma(DE:2RH)
€8.000.00 (0.00%)
DE:2RH
RedHill Biopharma financials statements
€8.00
At close:0.00 (0.00%)
RedHill Biopharma (2RH) Ratios
5 Followers
RedHill Biopharma Ratios
DE:2RH's free cash flow for Q2 2026 was $-4.58M. For the 2026 fiscal year, DE:2RH's free cash flow was decreased by $-14.00K and operating cash flow was $-4.56M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.34 | 0.54 | 0.84 | 0.44 | 1.09 |
| Quick Ratio | 0.34 | 0.37 | 0.61 | 0.38 | 0.91 |
| Cash Ratio | 0.21 | 0.21 | 0.29 | 0.10 | 0.36 |
| Solvency Ratio | -0.00 | -0.34 | 1.23 | -0.31 | -0.46 |
| Operating Cash Flow Ratio | -0.50 | -0.42 | -1.86 | -0.15 | -0.80 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -26.54 | -49.89 | -0.25 | -40.20 |
| Net Current Asset Value | $ -14.55M | $ -10.81M | $ -4.84M | $ -121.37M | $ -83.16M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.02 | 0.05 | 0.77 | 0.48 |
| Debt-to-Equity Ratio | 0.25 | -0.08 | 0.57 | -2.53 | 9.89 |
| Debt-to-Capital Ratio | 0.20 | -0.08 | 0.36 | 1.65 | 0.91 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.90 |
| Financial Leverage Ratio | 5.94 | -3.85 | 11.14 | -3.28 | 20.42 |
| Debt Service Coverage Ratio | -402.74 | -18.61 | 24.21 | -0.14 | -3.47 |
| Interest Coverage Ratio | -416.26 | -265.69 | 34.42 | -1.04 | -4.90 |
| Debt to Market Cap | 0.00 | 0.02 | 0.04 | 6.63 | 0.36 |
| Interest Debt Per Share | 0.34 | 0.17 | 2.97 | 1324.29 | 1121.70 |
| Net Debt to EBITDA | 0.38 | 0.56 | -0.17 | -4.63 | -0.93 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 60.31% | 47.03% | 46.06% | 42.39% |
| EBIT Margin | -2818.53% | -102.11% | 371.87% | -49.09% | -94.66% |
| EBITDA Margin | -2675.52% | -94.42% | 402.34% | -35.89% | -73.50% |
| Operating Profit Margin | -2765.38% | -181.69% | 193.45% | -69.33% | -94.61% |
| Pretax Profit Margin | -2825.17% | -102.80% | 366.25% | -115.97% | -113.98% |
| Net Profit Margin | -150.00% | -102.80% | 366.25% | -115.97% | -113.98% |
| Continuous Operations Profit Margin | -2825.17% | -102.80% | 366.25% | -115.97% | -113.98% |
| Net Income Per EBT | 5.31% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 102.16% | 56.58% | 189.33% | 167.28% | 120.47% |
| Return on Assets (ROA) | -1.69% | -45.82% | 103.77% | -45.11% | -53.95% |
| Return on Equity (ROE) | -10.05% | 176.55% | 1155.91% | 148.08% | -1101.34% |
| Return on Capital Employed (ROCE) | -129.15% | 349.59% | 331.98% | 111.04% | -81.36% |
| Return on Invested Capital (ROIC) | -125.66% | 420.64% | 241.02% | -55.17% | -78.81% |
| Return on Tangible Assets | -2.14% | -66.17% | 136.90% | -76.86% | -89.23% |
| Earnings Yield | -13.18% | -54.02% | 126.43% | -412.43% | -40.71% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.12 | 2.26 | 1.99 | 1.63 | 2.64 |
| Payables Turnover | 0.00 | 0.41 | 1.06 | 7.88 | 4.24 |
| Inventory Turnover | 0.00 | 0.87 | 0.79 | 3.03 | 3.34 |
| Fixed Asset Turnover | 0.26 | 18.41 | 5.52 | 8.59 | 20.31 |
| Asset Turnover | 0.01 | 0.45 | 0.28 | 0.39 | 0.47 |
| Working Capital Turnover Ratio | -0.02 | -1.20 | -0.11 | -1.19 | 34.71 |
| Cash Conversion Cycle | 3163.76 | -319.58 | 300.85 | 297.92 | 161.67 |
| Days of Sales Outstanding | 3163.76 | 161.83 | 183.62 | 223.70 | 138.43 |
| Days of Inventory Outstanding | 0.00 | 417.49 | 463.14 | 120.54 | 109.41 |
| Days of Payables Outstanding | 0.00 | 898.89 | 345.90 | 46.31 | 86.17 |
| Operating Cycle | 3163.76 | 579.31 | 646.75 | 344.23 | 247.84 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.05 | -3.80 | -69.12 | -235.63 | -699.02 |
| Free Cash Flow Per Share | -3.06 | -3.81 | -69.14 | -237.23 | -700.26 |
| Dividend Paid and CapEx Coverage Ratio | -1930.20 | -1041.00 | -3256.36 | -147.40 | -565.63 |
| Capital Expenditure Coverage Ratio | -1930.20 | -1041.00 | -3256.36 | -147.40 | -565.63 |
| Operating Cash Flow Coverage Ratio | -9.02 | -26.32 | -30.54 | -0.24 | -0.74 |
| Operating Cash Flow to Sales Ratio | -33.74 | -1.16 | -5.49 | -0.47 | -0.76 |
| Free Cash Flow Yield | -296.75% | -61.27% | -189.42% | -169.09% | -27.14% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.58 | -0.89 | 0.79 | -0.24 | -2.46 |
| Price-to-Sales (P/S) Ratio | 11.38 | 1.90 | 2.90 | 0.28 | 2.80 |
| Price-to-Book (P/B) Ratio | 0.76 | -3.27 | 9.14 | -0.36 | 27.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.34 | -1.63 | -0.53 | -0.59 | -3.68 |
| Price-to-Operating Cash Flow Ratio | -0.34 | -1.63 | -0.53 | -0.60 | -3.69 |
| Price-to-Earnings Growth (PEG) Ratio | 0.08 | 0.01 | -0.01 | 0.01 | 0.00 |
| Enterprise Value Multiple | -0.05 | -1.45 | 0.55 | -5.41 | -4.73 |
| Enterprise Value | 352.95K | 11.04M | 14.52M | 120.10M | 298.42M |
| EV to EBITDA | -0.05 | -1.45 | 0.55 | -5.41 | -4.73 |
| EV to Sales | 1.23 | 1.37 | 2.22 | 1.94 | 3.48 |
| EV to Free Cash Flow | -0.04 | -1.18 | -0.41 | -4.09 | -4.58 |
| EV to Operating Cash Flow | -0.04 | -1.18 | -0.41 | -4.12 | -4.59 |
| Tangible Book Value Per Share | -0.32 | -4.15 | -6.77 | -920.62 | -674.54 |
| Shareholders’ Equity Per Share | 1.35 | -1.90 | 3.99 | -390.77 | 95.37 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.09 | 3.26 | 12.60 | 498.96 | 921.58 |
| Net Income Per Share | -0.14 | -3.35 | 46.15 | -578.64 | -1050.40 |
| Tax Burden | 0.05 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.01 | 0.98 | 2.36 | 1.20 |
| Research & Development to Revenue | 7.07 | 0.20 | 0.54 | 0.12 | 0.34 |
| SG&A to Revenue | 21.58 | 1.93 | 4.42 | 0.89 | 0.89 |
| Stock-Based Compensation to Revenue | 1.60 | 0.08 | 0.25 | 0.09 | 0.12 |
| Income Quality | 22.50 | 1.13 | -1.50 | 0.41 | 0.67 |
Currency in USD
